Hereditary angioedema

被引:0
|
作者
Aygoeren-Puersuen, Emel [1 ]
Bork, Konrad [2 ]
机构
[1] Goethe Univ, Univ Klinikum Frankfurt, Klin Kinder & Jugendmed, Angioodem Ambulanz & Interdisziplinares Comprehen, Theodor Stern Kai 7, D-60590 Frankfurt, Germany
[2] Univ Med Mainz, Hautklin, Mainz, Germany
来源
PADIATRIE UND PADOLOGIE | 2020年 / 55卷 / 01期
关键词
Complement C1 inhibitor protein; Factor XII; Bradykinin; Hereditary angioedema; Prophylaxis; angioedema; ATTACKS; INHIBITOR; PROPHYLAXIS; PREVENTION; MUTATIONS; C1-INH; GENE;
D O I
10.1007/s00608-019-00738-4
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Hereditary angioedema (HAE) comprises a heterogeneous group of diseases with similar phenotypes but different underlying genotypes. Specific clinical signs may point to HAE as opposed to histaminergic angioedema: the typical prolonged development of angioedema over time, positive family history, a lack of response to antihistamines and steroids and response to bradykinin antagonists are typical signs of HAE. The different types of HAE may be associated with a severe clinical course. They are life-long conditions and are still potentially life-threatening. The quality of life of patients with HAE may be considerably impaired. Management plans should be individualized, which is facilitated by the variety of specific medicastions available.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 50 条
  • [41] Could it be hereditary angioedema?-Perspectives from different medical specialties
    Magerl, Markus
    Sala-Cunill, Anna
    Weber-Chrysochoou, Christina
    Trainotti, Susanne
    Mormile, Ilaria
    Spadaro, Giuseppe
    CLINICAL AND TRANSLATIONAL ALLERGY, 2023, 13 (09)
  • [42] Cinryze™ (C1-inhibitor) for the treatment of hereditary angioedema
    Gompels, Mark M.
    Lock, Robert John
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (05) : 569 - 573
  • [43] Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights
    Petkova, Elena
    Yordanova, Vanya
    Staevska, Maria
    Valerieva, Anna
    DRUG HEALTHCARE AND PATIENT SAFETY, 2022, 14 : 195 - 210
  • [44] Consensus on treatment goals in hereditary angioedema: A global Delphi initiative
    Maurer, Marcus
    Aygoren-Pursun, Emel
    Banerji, Aleena
    Bernstein, Jonathan A.
    Boysen, Henrik Balle
    Busse, Paula J.
    Bygum, Anette
    Caballero, Teresa
    Castaldo, Anthony J.
    Christiansen, Sandra C.
    Craig, Timothy
    Farkas, Henriette
    Grumach, Anete S.
    Hide, Michihiro
    Katelaris, Constance H.
    Li, H. Henry
    Longhurst, Hilary
    Lumry, William R.
    Magerl, Markus
    Martinez-Saguer, Inmaculada
    Riedl, Marc A.
    Zhi, Yuxiang
    Zuraw, Bruce
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 148 (06) : 1526 - 1532
  • [45] A safety review of prophylaxis drugs for adolescent patients with hereditary angioedema
    Farkas, Henriette
    Balla, Zsuzsanna
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (07) : 549 - 561
  • [46] An update on the genetics and pathogenesis of hereditary angioedema
    Banday, Aaqib Zaffar
    Kaur, Anit
    Jindal, Ankur Kumar
    Rawat, Amit
    Singh, Surjit
    GENES & DISEASES, 2020, 7 (01) : 75 - 83
  • [47] A review of berotralstat for the treatment of hereditary angioedema
    Farkas, Henriette
    Balla, Zsuzsanna
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2023, 19 (02) : 145 - 153
  • [48] Lanadelumab for the prevention of attacks in hereditary angioedema
    Valerieva, Anna
    Senter, Riccardo
    Wu, Maddalena Alessandra
    Zanichelli, Andrea
    Cicardi, Marco
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (12) : 1239 - 1248
  • [49] A Comprehensive Management Approach in Pediatric and Adolescent Patients With Hereditary Angioedema
    Tachdjian, Raffi
    Kaplan, Allen P.
    CLINICAL PEDIATRICS, 2023, 62 (09) : 973 - 980
  • [50] Hereditary angioedema. A therapeutic guide
    Malbran, Alejandro
    Fernandez Romero, Diego S.
    Menendez, Alejandra
    MEDICINA-BUENOS AIRES, 2012, 72 (02) : 119 - 123